Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
|Webcasts|May 28, 2020
Now and Next: A COVID-19 Access and Patient Engagement Update
Author(s)IQVIA
What market access looks like now and what’s next – a COVID-19 perspective from IQVIA. Live: Thursday, May 28, 2020, 2020 at 11am EDT On demand available after airing until May 28, 2021. Register free
Register free:
EVENT OVERVIEW:
COVID-19 is front of mind for everybody. Many voices in the industry – including IQVIA – are releasing their own reports, updates, and estimates for what COVID-19 means for our businesses and clients. In this webinar, we will bring many of these dynamics together and lay the groundwork for pharma’s response to these uncertain times.
3 KEY TAKE-AWAYS:
- The impact to of shelter-in place protocols on pharmaceutical demand and the underlying drivers
- Shifting channel dynamics and the impact on manufacturer margin
- Geographic variations for impact and recovery
Speaker: Luke Greenwalt, Vice President, US Market Access Center of Excellence, IQVIA
Time and date: Thursday, May 28, 2020, 2020 at 11am EDT
On demand available after airing until May 28, 2021.
Sponsor: IQVIA
Register free:
Related to this article
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Trending on PharmExec
1
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
2
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
5